Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced C...
June 06 2017 - 7:15AM
Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing
company, and San Raffaele University and Research Hospital, a
leading scientific institution, have entered into a three-year
research collaboration, option and license agreement to engineer
optimized T cell cancer therapies. The goal of the
collaboration is to discover innovative tools to target
tough-to-treat cancers, while leveraging Intellia’s proprietary
CRISPR/Cas9 platform to generate next-generation T cell therapies
that will address unmet needs in both hematological and solid
tumors. Professor Chiara Bonini, Head of San Raffaele’s
Experimental Hematology Unit and Deputy Director of the Division of
Immunology, Transplantation and Infectious Diseases, will lead the
scientific work at San Raffaele.
The collaboration marks the first external partnership of
Intellia’s eXtellia division. eXtellia’s long-term strategy is
focused on advancing new generations of engineered cell therapies
through the unique and proprietary applications of CRISPR genome
editing. eXtellia was established in 2016, and has identified its
initial areas of focus as immuno-oncology and auto-immunity, where
genome-edited cell therapy offers a potentially powerful and
differentiated therapeutic modality. The agreement also includes
options and licenses to key technologies for production of
engineered cell therapies developed at San Raffaele.
“Through this collaboration, eXtellia aims to apply CRISPR/Cas9
genome editing in a multi-faceted way to modulate the fundamental
properties of engineered immune cells and amplify their anti-cancer
properties far beyond current applications,” said Andrew
Schiermeier, Ph.D., Senior Vice President, eXtellia. “San Raffaele
and Dr. Bonini are recognized globally as leaders in cell therapy
and immuno-oncology, with excellent track records in translating
innovative research into approved therapies. We aspire to one day
cure cancer in patients who are fighting every day with few or no
treatment options.”
“T cell therapy has recently produced impressive results in
clinical trials in specific cancer types. However, to realize the
full potential of T cell therapy, including in a broader set of
cancer types, next generation cellular products are needed,” said
Professor Chiara Bonini. “Intellia’s leadership in genome editing
will be critical to achieve this goal and shape this new class of
‘living drugs’.”
About San Raffaele University and Research
Hospital
Ospedale San Raffaele is a research-university hospital
established in 1971 to provide international-level specialised care
for the most complex and difficult health conditions. Since 2012,
it is part of San Donato Hospital Group, the leading hospital group
in Italy. San Raffaele is a multi-speciality center with over 50
clinical specialties and over 1,300 beds. Research focuses on
integrating basic, translational and clinical activities to provide
the most advanced care to its patients. For further information,
visit: hsr.it.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Intellia within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but
are not limited to, express or implied statements regarding
Intellia’s ability to advance and expand the CRISPR/Cas9 technology
to develop into human therapeutic products; our ability to achieve
stable liver editing; effective genome editing with a single
treatment dose; and the potential timing and advancement of our
preclinical studies and clinical trials. Any forward-looking
statements in this press release are based on management’s current
expectations and beliefs of future events, and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: risks related to
Intellia’s ability to protect and maintain our intellectual
property position; risks related to the ability of our licensors to
protect and maintain their intellectual property position;
uncertainties related to the initiation and conduct of studies and
other development requirements for our product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; the risk that the
results of preclinical studies will be predictive of future results
in connection with future studies; and the risk that Intellia’s
collaborations with Novartis or Regeneron will not continue or will
not be successful. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Intellia’s actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in Intellia’s most recent annual report on Form 10-K filed
with the Securities and Exchange Commission, as well as discussions
of potential risks, uncertainties, and other important factors in
Intellia’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Intellia Therapeutics undertakes no duty to
update this information unless required by law.
Contacts:
Intellia Therapeutics
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
Graeme Bell
Executive Vice President, Chief Financial Officer
+1 857-706-1071
graeme.bell@intelliatx.com
Ospedale San Raffaele - University and Research Hospital
Press office:
Gea Gardini + 39 02.2643.3004
ufficio.stampa@hsr.it
www.hsr.it
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Oct 2023 to Oct 2024